Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class
- PMID: 20143641
- DOI: 10.1016/j.anai.2009.11.020
Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class
Abstract
Objective: To evaluate how well the medications currently approved in the United States for allergic rhinitis (AR) treat nasal symptoms when examined according to Food and Drug Administration-indicated uses and dosages.
Data sources: MEDLINE (1966 onward), EMBASE (1974 onward), and the Cochrane Library (2007) were systematically searched according to the following criteria defined at a roundtable meeting of the authors: randomized controlled trial, at least a 2-week duration, and approved indication and dosage in the United States.
Study selection: Data from studies that met the inclusion criteria were extracted into evidence tables, which were reviewed twice by the full panel of authors. Individual panel members also were asked to comment on abstracts, articles, and summary tables based on their known expertise. The entire faculty approved the selection of studies included in this review.
Results: Fifty-four randomized, placebo-controlled studies involving more than 14,000 adults and 1,580 children with AR met the criteria for review: 38 studies of seasonal allergic rhinitis (SAR; n = 11,980 adults and 946 children) and 12 studies of perennial allergic rhinitis (PAR; n = 3,800 adults and 366 children). The median percentage changes from baseline for total nasal symptom score for SAR were as follows: nasal antihistamines, -22.2%; oral antihistamines, -23.5%; intranasal steroids (INSs), -40.7%; and placebo, -15.0%. For PAR, the changes were as follows: oral antihistamines, -51.4%; INSs, -37.3%; and placebo, -24.8%. Data for mediator antagonists were limited.
Conclusions: The data, although limited, confirm that INSs produce the greatest improvements in nasal symptoms in patients with SAR. In addition, INSs are effective for PAR, but the data were of variable quality, and oral antihistamines may be equally effective for some patients. The reporting of published data should be standardized to permit better comparisons in future studies.
Comment in
-
Evaluating the effectiveness of medications in the treatment of allergic rhinitis.Ann Allergy Asthma Immunol. 2010 Aug;105(2):189; author reply 189. doi: 10.1016/j.anai.2010.05.019. Ann Allergy Asthma Immunol. 2010. PMID: 20674835 No abstract available.
Similar articles
-
Levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children.Clin Ther. 2009 Aug;31(8):1664-87. doi: 10.1016/j.clinthera.2009.08.015. Clin Ther. 2009. PMID: 19808127 Review.
-
Azelastine and olopatadine in the treatment of allergic rhinitis.Ann Allergy Asthma Immunol. 2009 Nov;103(5):373-80. doi: 10.1016/S1081-1206(10)60355-9. Ann Allergy Asthma Immunol. 2009. PMID: 19927534 Review.
-
Treatment of allergic rhinitis: an evidence-based evaluation of nasal corticosteroids versus nonsedating antihistamines.Am J Manag Care. 1998 Jan;4(1):89-96. Am J Manag Care. 1998. PMID: 10179909
-
Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis.Pharmacotherapy. 2007 Jun;27(6):852-9. doi: 10.1592/phco.27.6.852. Pharmacotherapy. 2007. PMID: 17542768
-
Evaluation of the drug monitoring programme of azelastine hydrochloride nasal spray in the treatment of allergic rhinitis in children under 13 years of age.Arzneimittelforschung. 1997 Jul;47(7):841-4. Arzneimittelforschung. 1997. PMID: 9272242 Clinical Trial.
Cited by
-
Office-Based Blue Laser Versus Coblation Therapy for Inferior Turbinate Hypertrophy: A Pilot Study.OTO Open. 2025 May 14;9(2):e70127. doi: 10.1002/oto2.70127. eCollection 2025 Apr-Jun. OTO Open. 2025. PMID: 40370997 Free PMC article.
-
Circulating C-X-C Motif Ligand 13 as a Biomarker for Early Predicting Efficacy of Subcutaneous Immunotherapy in Children With Chronic Allergic Rhinitis.Front Pediatr. 2022 May 4;10:872152. doi: 10.3389/fped.2022.872152. eCollection 2022. Front Pediatr. 2022. PMID: 35601415 Free PMC article.
-
Non-allergic rhinitis in children: Epidemiological aspects, pathological features, diagnostic methodology and clinical management.World J Methodol. 2016 Dec 26;6(4):200-213. doi: 10.5662/wjm.v6.i4.200. eCollection 2016 Dec 26. World J Methodol. 2016. PMID: 28074172 Free PMC article. Review.
-
The need for patient-focused therapy for children and teenagers with allergic rhinitis: a case-based review of current European practice.Clin Transl Allergy. 2015 Jan 24;5(1):2. doi: 10.1186/s13601-014-0044-5. eCollection 2015. Clin Transl Allergy. 2015. PMID: 25657844 Free PMC article.
-
Treatment of Early Allergic and Late Inflammatory Symptoms of Allergic Rhinitis with Petasites hybridus Leaf Extract (Ze 339): Results of a Noninterventional Observational Study in Switzerland.Pharmaceuticals (Basel). 2021 Feb 24;14(3):180. doi: 10.3390/ph14030180. Pharmaceuticals (Basel). 2021. PMID: 33668395 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous